Electrophysiology Devices Market Size, Share, Growth Analysis, By Type(Ablation Catheters (Radiofrequency (RF) Ablation, Cryoablation, Pulse Field Ablation) Diagnostic Catheters, Laboratory Devices and Access Devices), By Indication(Atrial Fibrillation (AF), and Non-Atrial Fibrillation), By End-Use(Inpatient Facilities, Outpatient Facilities and Others), By Region - Industry Forecast 2024-2031

In March 2024, The US Food and Drug Administration (FDA) issued 510(k) clearance to Synaptive Medical’s near-infrared (NIR) fluorescence visualization module, Modus IR. 

In February 2024, US-based nanoscience company EVŌQ Nano’s antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated in healthcare-associated infections (HAIs).  

In January 2024, The European Commission (EC) has proposed an extension of the transition period for the IVDR, aiming to maintain the availability of essential healthcare products and ensure patient care. 

In May 2022, BioSig Technologies, Inc., a medical tech company, began a statewide commercial introduction campaign. BioSig has made significant contributions to the transfer of its Purity EP System from an exclusive market launch to a countrywide launch. The PURE EP(TM) is a 510(k) certified non-invasive type II device designed to improve procedural effectiveness and efficiency in cardiac electrophysiology. 

In November 2021, India Medtronic Private Limited, a wholly-owned division of Medtronic plc, announces the launch of the Arctic Front Cardiac Cryoablation Catheters The System, the first and only cryoballoon catheters approved by CDSCO for the management of ventricular fibrillation (AF) in Indian.